Glenmark debuts Olopatadine Hydrochloride Ophthalmic Solution OTC
Glenmark has launched Olopatadine Hydrochloride Ophthalmic Solution, 0.1% (OTC).
The company said its product compares to the active ingredient found in Pataday2 Twice Daily Relief.
Pataday Twice Daily Relief (OTC) had a market value of roughly $26.4 million, per the latest Nielsen Syndicated data for the 52-week period ending July 13, 2024.
[Read more FDA grants Glenmark tentative approval for generic Enstilar]
Fabio Moreno, head of OTC sales and marketing at Glenmark said, “We are excited to announce the launch of Olopatadine Ophthalmic Solution USP, 0.1%, addressing the growing demand for a new supplier in this category. This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers.”